THE LATEST FROM RAKOVINA
Discovery in motion.
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
Download Vancouver, British Columbia – June 6, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery,...
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated. Vancouver, British Columbia, June 2, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing novel DNA-damage response...
Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer
DOWNLOAd Vancouver, British Columbia, May 5, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is...
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
VANCOUVER, British Columbia, May 28, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company dated May 29, 2023 (the...
Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation
$3 Million Lead Order from Strategic Investors Supports Bold Transformation Vancouver, British Columbia, May 15, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies...
Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer
Vancouver, British Columbia, May 5, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to...
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
Vancouver, British Columbia, April 30, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery announced the financial results for its...
Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies Vancouver, British Columbia, April 29, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing...
Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel
Vancouver, British Columbia, April 29, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the appointments of...
Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery
Vancouver, British Columbia, April 22, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to congratulate...
Rakovina Therapeutics Unveils Preclinical Data at the AACR – World’s Premier Cancer Research Forum
Cutting-Edge Research Results Showcase AI-Powered Drug Discovery Vancouver, British Columbia, Mar 25, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence...
Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing
Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignancies Vancouver, British Columbia, March 12, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company...
